1
Liu J,---Lo GH. Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected with HBV. Gastroenterology 2018; 154:989-997.
2
Chuang WL1, Chien RN2, Peng CY3, Chang TT4, Lo GH5, Sheen IS6, Wang HY7, Chen JJ8, Yang JC9, Knox SJ9, Gao B9,Garrison KL9, Mo H9, Pang PS9, Hsu YC10, Hu TH11, Chu CJ12, Kao JH. Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus. J Gastroenterol Hepatol 2016; 31: 1323-9.
3
Kao JH1, Chien RN2, Chang TT3, Peng CY4, Hu TH5, Lo GH6, Wang HY7, Chen JJ8, Yang JC9, Knox SJ9, Han L9, Mo H9,Mathias A9, Brainard DM9, Sheen IS10, Hsu YC11, Chu CJ12, Chuang WL.. A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection. Liver int 2016; 36:1101-7.
4
Benralizumab for the Prevention of COPD Exacerbations.
Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, Sin DD, Vogelmeier CF, Sciurba FC, Bafadhel M, Backer V, Kato M, Ramírez-Venegas A, Wei YF, Bjermer L, Shih VH, Jison M, O'Quinn S, Makulova N, Newbold P, Goldman M, Martin UJ; GALATHEA Study Investigators; TERRANOVA Study Investigators.
N Engl J Med. 2019 Sep 12;381(11):1023-1034. doi: 10.1056/NEJMoa1905248. Epub 2019 May 20.
5
Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report.
Chih-Hsin Yang J, Shepherd FA, Kim DW, Lee GW, Lee JS, Chang GC, Lee SS, Wei YF, Lee YG, Laus G, Collins B, Pisetzky F, Horn L.
J Thorac Oncol. 2019 May;14(5):933-939. doi: 10.1016/j.jtho.2019.02.001. Epub 2019 Feb 11.
